{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:49:10Z","timestamp":1792316950020,"version":"4.4.0"},"reference-count":312,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["81802718"],"award-info":[{"award-number":["81802718"]}]},{"name":"National Natural Science Foundation of China","award":["U1504817"],"award-info":[{"award-number":["U1504817"]}]},{"name":"National Natural Science Foundation of China","award":["192102310151"],"award-info":[{"award-number":["192102310151"]}]},{"name":"National Natural Science Foundation of China","award":["202102310480"],"award-info":[{"award-number":["202102310480"]}]},{"name":"National Natural Science Foundation of China","award":["2020GGJS038"],"award-info":[{"award-number":["2020GGJS038"]}]},{"name":"Foundation of Science and Technology Department of Henan Province, China","award":["81802718"],"award-info":[{"award-number":["81802718"]}]},{"name":"Foundation of Science and Technology Department of Henan Province, China","award":["U1504817"],"award-info":[{"award-number":["U1504817"]}]},{"name":"Foundation of Science and Technology Department of Henan Province, China","award":["192102310151"],"award-info":[{"award-number":["192102310151"]}]},{"name":"Foundation of Science and Technology Department of Henan Province, China","award":["202102310480"],"award-info":[{"award-number":["202102310480"]}]},{"name":"Foundation of Science and Technology Department of Henan Province, China","award":["2020GGJS038"],"award-info":[{"award-number":["2020GGJS038"]}]},{"name":"Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province","award":["81802718"],"award-info":[{"award-number":["81802718"]}]},{"name":"Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province","award":["U1504817"],"award-info":[{"award-number":["U1504817"]}]},{"name":"Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province","award":["192102310151"],"award-info":[{"award-number":["192102310151"]}]},{"name":"Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province","award":["202102310480"],"award-info":[{"award-number":["202102310480"]}]},{"name":"Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province","award":["2020GGJS038"],"award-info":[{"award-number":["2020GGJS038"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Central nervous system disorders, especially neurodegenerative diseases, are a public health priority and demand a strong scientific response. Various therapy procedures have been used in the past, but their therapeutic value has been insufficient. The blood\u2013brain barrier (BBB) and the blood\u2013cerebrospinal fluid barrier is two of the barriers that protect the central nervous system (CNS), but are the main barriers to medicine delivery into the CNS for treating CNS disorders, such as brain tumors, Parkinson\u2019s disease, Alzheimer\u2019s disease, and Huntington\u2019s disease. Nanotechnology-based medicinal approaches deliver valuable cargos targeting molecular and cellular processes with greater safety, efficacy, and specificity than traditional approaches. CNS diseases include a wide range of brain ailments connected to short- and long-term disability. They affect millions of people worldwide and are anticipated to become more common in the coming years. Nanotechnology-based brain therapy could solve the BBB problem. This review analyzes nanomedicine\u2019s role in medication delivery; immunotherapy, chemotherapy, and gene therapy are combined with nanomedicines to treat CNS disorders. We also evaluated nanotechnology-based approaches for CNS disease amelioration, with the intention of stimulating the immune system by delivering medications across the BBB.<\/jats:p>","DOI":"10.3390\/molecules28031283","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T02:01:18Z","timestamp":1675044078000},"page":"1283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders"],"prefix":"10.3390","volume":"28","author":[{"given":"Zi-Hua","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Neurology, Kaifeng Hospital of Traditional Chinese Medicine, No. 54 East Caizhengting St., Kaifeng 475000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadullah","family":"Khattak","sequence":"additional","affiliation":[{"name":"Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-2208","authenticated-orcid":false,"given":"Mohd Ahmar","family":"Rauf","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-5479","authenticated-orcid":false,"given":"Mohammad Azam","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Epidemic Disease Research, Institute for Research & Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-4377","authenticated-orcid":false,"given":"Mohammad N.","family":"Alomary","sequence":"additional","affiliation":[{"name":"National Centre for Biotechnology, King Abdulaziz City for Science and Technology (KACST), P.O. Box 6086, Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-5158","authenticated-orcid":false,"given":"Sufyan","family":"Razak","sequence":"additional","affiliation":[{"name":"Dow Medical College, John Hopkins Medical Center, School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Nursing and Health, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-8437","authenticated-orcid":false,"given":"Dong-Dong","family":"Wu","sequence":"additional","affiliation":[{"name":"Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"},{"name":"School of Stomatology, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ying","family":"Ji","sequence":"additional","affiliation":[{"name":"Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/ar200019c","article-title":"Theranostic nanomedicine","volume":"44","author":"Lammers","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.tibtech.2018.01.006","article-title":"Nanotechnology-based strategies for siRNA brain delivery for disease therapy","volume":"36","author":"Zheng","year":"2018","journal-title":"Trends Biotechnol."},{"key":"ref_3","first-page":"67","article-title":"Role of extracellular vesicles in human diseases","volume":"5","author":"Tayyba","year":"2019","journal-title":"Biomed. Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMra0912273","article-title":"Nanomedicine","volume":"363","author":"Kim","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.apsb.2021.01.010","article-title":"Recent developments in the medicinal chemistry of single boron atom-containing compounds","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","article-title":"Boron in drug design: Recent advances in the development of new therapeutic agents","volume":"179","author":"Fernandes","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.2174\/0929867326666190327154954","article-title":"Turning fear of boron toxicity into boron-containing drug design","volume":"26","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1021\/acs.jcim.1c00262","article-title":"A Boron-Containing Compound Acting on Multiple Targets Against Alzheimer\u2019s Disease. Insights from Ab Initio and Molecular Dynamics Simulations","volume":"61","author":"Ritacca","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bmcl.2012.11.068","article-title":"Discovery of alkenylboronic acids as neuroprotective agents affecting multiple biological targets involved in Alzheimer\u2019s disease","volume":"23","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1039\/C8MD00315G","article-title":"Discovery of boron-containing compounds as A\u03b2 aggregation inhibitors and antioxidants for the treatment of Alzheimer\u2019s disease","volume":"9","author":"Lu","year":"2018","journal-title":"MedChemComm"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Maiti, P., Manna, J., Burch, Z.N., Flaherty, D.B., Larkin, J.D., and Dunbar, G.L. (2020). Ameliorative Properties of Boronic Compounds in In Vitro and In Vivo Models of Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186664"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Amiji, M.M. (2006). Nanotechnology for Cancer Therapy, CRC Press.","DOI":"10.1201\/9781420006636"},{"key":"ref_13","first-page":"25","article-title":"Therapeutic nanoparticles: State-of-the-art of nanomedicine","volume":"1","author":"Athar","year":"2014","journal-title":"Adv. Mater. Rev"},{"key":"ref_14","first-page":"1373","article-title":"Nanomedicine: Why it still taking long from \u201cbench to bedside\u201d?","volume":"4","author":"Rehman","year":"2018","journal-title":"Biomed. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","article-title":"Intranasal Treatment of Central Nervous System Dysfunction in Humans","volume":"30","author":"Chapman","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/17435889.2.5.669","article-title":"Biodegradable, polymeric nanoparticle delivery systems for cancer therapy","volume":"2","author":"Pridgen","year":"2007","journal-title":"Nanomedicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nbt1006-1211","article-title":"The emerging nanomedicine landscape","volume":"24","author":"Wagner","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphys.2018.00170","article-title":"Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy","volume":"9","author":"Qutub","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.pharmtox.44.101802.121631","article-title":"Neurogenesis IN THE Adult Brain: New","volume":"44","author":"Lie","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"New England J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1575","DOI":"10.1002\/wnan.1575","article-title":"Immunoengineering in glioblastoma imaging and therapy","volume":"11","author":"Zanganeh","year":"2019","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41401-020-0429-z","article-title":"Nanomedicine-based immunotherapy for central nervous system disorders","volume":"41","author":"Hanif","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1017\/S104161021800011X","article-title":"Use of FDA approved medications for Alzheimer\u2019s disease in mild dementia is associated with reduced informal costs of care","volume":"30","author":"Behrens","year":"2018","journal-title":"Int. Psychogeriatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1039\/D2SC03948F","article-title":"Bicyclobutanes: From curiosities to versatile reagents and covalent warheads","volume":"13","author":"Kelly","year":"2022","journal-title":"Chem. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.bmcl.2017.07.075","article-title":"Current approaches to the treatment of Parkinson\u2019s Disease","volume":"27","author":"Ellis","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1021\/acs.chemrev.0c01263","article-title":"Chemical aspects of human and environmental overload with fluorine","volume":"121","author":"Han","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2350::AID-CNCR20>3.0.CO;2-R","article-title":"Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy","volume":"88","author":"Madajewicz","year":"2000","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1021\/acs.chemrev.1c00332","article-title":"Technological innovations in photochemistry for organic synthesis: Flow chemistry, high-throughput experimentation, scale-up, and photoelectrochemistry","volume":"122","author":"Buglioni","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaci.2004.03.024","article-title":"Mechanisms of immunotherapy","volume":"113","author":"Till","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1021\/acs.nanolett.8b02340","article-title":"Immunomodulating nanomedicine for cancer therapy","volume":"18","author":"Liu","year":"2018","journal-title":"Nano Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41565-020-00810-2","article-title":"Inducing immune tolerance with dendritic cell-targeting nanomedicines","volume":"16","author":"Desai","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.wneu.2017.07.179","article-title":"Correlation of circulating T lymphocytes and intracranial hypertension in intracerebral hemorrhage","volume":"107","author":"Su","year":"2017","journal-title":"World Neurosurg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tips.2016.12.001","article-title":"Brain pericytes as mediators of neuroinflammation","volume":"38","author":"Rustenhoven","year":"2017","journal-title":"Trends pharmacolo. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrn752","article-title":"Innate immunity: The missing link in neuroprotection and neurodegeneration?","volume":"3","author":"Nguyen","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-065X.2012.01130.x","article-title":"Regulatory T cells in the central nervous system","volume":"248","author":"Lowther","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_44","first-page":"201","article-title":"Immunotherapy for glioblastoma: On the sidelines or in the game?","volume":"24","author":"Reardon","year":"2017","journal-title":"Discov. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in GlioblastomaT-Cell Exhaustion Signatures in Glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1172\/JCI90603","article-title":"Understanding the functions and relationships of the glymphatic system and meningeal lymphatics","volume":"127","author":"Louveau","year":"2017","journal-title":"J. Clin. Invest."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-13-2057","article-title":"Immunotherapy for Brain Cancer: Recent Progress and Future PromiseImmunotherapy for Brain Cancer","volume":"20","author":"Jackson","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.drudis.2019.01.006","article-title":"Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases","volume":"24","author":"Tomitaka","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1002\/wnan.1479","article-title":"Nanotherapeutic systems for local treatment of brain tumors","volume":"10","author":"Chakroun","year":"2018","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnology"},{"key":"ref_53","unstructured":"Rauf, M.A., Rehman, F.U., Zheng, M., and Shi, B. (2019). Nanomedicine in Brain Diseases, Springer."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3171\/2014.10.JNS14229","article-title":"Convection-enhanced delivery to the central nervous system","volume":"122","author":"Lonser","year":"2015","journal-title":"J. Neurosurg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: New opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood\u2013brain barrier shuttle peptides: An emerging paradigm for brain delivery","volume":"45","author":"Giralt","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood\u2013brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1021\/acsnano.5b05341","article-title":"Penetrating the blood\u2013brain barrier: Promise of novel nanoplatforms and delivery vehicles","volume":"9","author":"Ali","year":"2015","journal-title":"ACS Nano"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1021\/acs.nanolett.9b04683","article-title":"Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy","volume":"20","author":"Liu","year":"2020","journal-title":"Nano Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1360\/SSC-2019-0068","article-title":"Cell-derived biomimetic drug delivery systems for cancer therapy","volume":"49","author":"He","year":"2019","journal-title":"Sci. Sin. Chim."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature05291","article-title":"The roles of intracellular protein-degradation pathways in neurodegeneration","volume":"443","author":"Rubinsztein","year":"2006","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1074\/jbc.R800065200","article-title":"Animal models of polyglutamine diseases and therapeutic approaches","volume":"284","author":"Marsh","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2003054","DOI":"10.1002\/adfm.202003054","article-title":"Recent advancements of nanomedicine in neurodegenerative disorders theranostics","volume":"30","author":"Mukherjee","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00726-009-0428-3","article-title":"Critical role of transglutaminase and other stress proteins during neurodegenerative processes","volume":"38","author":"Caccamo","year":"2010","journal-title":"Amino Acids"},{"key":"ref_68","unstructured":"Aderibigbe, B., Naki, T., and Owonubi, S. (2019). Handbook of Graphene Set, I-VIII, Wiley."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12012-019-09543-8","article-title":"Proarrhythmic Effect of Acetylcholine-Esterase Inhibitors Used in the Treatment of Alzheimer\u2019s Disease: Benefit of Rivastigmine in an Experimental Whole-Heart Model","volume":"20","author":"Ellermann","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jamaneurol.2017.3517","article-title":"Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: A phase 2 randomized clinical trial","volume":"75","author":"Schenkman","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","article-title":"Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer\u2019s disease-like transgenic mouse model","volume":"14","author":"Carradori","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11060-017-2413-0","article-title":"Immunotherapy and radiation in glioblastoma","volume":"134","author":"Sahebjam","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.it.2015.08.006","article-title":"Revisiting the mechanisms of CNS immune privilege","volume":"36","author":"Louveau","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"ra111","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1084\/jem.20142290","article-title":"A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_76","unstructured":"Ramos, M., Bechet, N.B., Battistella, R., Pavan, C., Xavier, A.L., Nedergaard, M., and Lundgaard, I. (2019). Astrocytes, Springer."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00401-016-1555-z","article-title":"Vascular basement membranes as pathways for the passage of fluid into and out of the brain","volume":"131","author":"Morris","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1038\/srep02582","article-title":"Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain","volume":"3","author":"Thrane","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_79","first-page":"15","article-title":"Immunity to homologous grafted skin. II. The relationship between the antigens of blood and skin","volume":"27","author":"Medawar","year":"1946","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nri3391","article-title":"Orchestrated leukocyte recruitment to immune-privileged sites: Absolute barriers versus educational gates","volume":"13","author":"Shechter","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/17425247.2016.1200557","article-title":"Harnessing nanomedicine for therapeutic intervention in glioblastoma","volume":"13","author":"Gutkin","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Birks, J.S., and Evans, J.G. (2015). Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst. Rev., 4.","DOI":"10.1002\/14651858.CD001191.pub3"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1801362","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood\u2013brain barrier: The role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/jcbfm.2013.135","article-title":"Blood\u2013brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease","volume":"33","author":"Erickson","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11307-012-0556-0","article-title":"P-glycoprotein function at the blood\u2013brain barrier: Effects of age and gender","volume":"14","author":"Lubberink","year":"2012","journal-title":"Mol. Imaging Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1021\/acschemneuro.7b00260","article-title":"Functionalization and characterization of magnetic nanoparticles for the detection of ferritin accumulation in Alzheimer\u2019s disease","volume":"9","author":"Desco","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajps.2018.09.005","article-title":"Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances","volume":"14","author":"Niu","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_88","first-page":"60","article-title":"Polymeric nanoparticles drug delivery to brain: A review","volume":"2","author":"Sharma","year":"2015","journal-title":"Int. J. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1021\/cr200472g","article-title":"Therapeutic benefits from nanoparticles: The potential significance of nanoscience in diseases with compromise to the blood brain barrier","volume":"113","author":"Krol","year":"2012","journal-title":"Chem. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/01.cco.0000245321.34658.f4","article-title":"Recent advances in immunotherapy for human glioma","volume":"18","author":"Carpentier","year":"2006","journal-title":"Curr. Opin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"He, Q., Liu, J., Liang, J., Liu, X., Li, W., Liu, Z., Ding, Z., and Tuo, D. (2018). Towards improvements for penetrating the blood\u2013brain barrier\u2014recent progress from a material and pharmaceutical perspective. Cells, 7.","DOI":"10.3390\/cells7040024"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1152\/physrev.00004.2013","article-title":"Cerebrospinal fluid secretion by the choroid plexus","volume":"93","author":"Damkier","year":"2013","journal-title":"Physiolo. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.2174\/1381612822666160726112115","article-title":"Potential pathways for CNS drug delivery across the blood-cerebrospinal fluid barrier","volume":"22","author":"Strazielle","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2012.06.032","article-title":"Influence of P-glycoprotein on brucine transport at the in vitro blood\u2013brain barrier","volume":"690","author":"Xu","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Machtoub, L., and Kasugai, Y. (2016). Amyotrophic Lateral Sclerosis: Advances and Perspectives of Neuronanomedicine, CRC Press.","DOI":"10.1201\/b15632"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJMc081511","article-title":"Cancer immunotherapy","volume":"359","author":"Rosenberg","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/14712598.2016.1214266","article-title":"Cellular immunotherapy for malignant gliomas","volume":"16","author":"Lin","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"432","DOI":"10.7150\/thno.8074","article-title":"Combining Microbubbles and Ultrasound for Drug Delivery to Brain Tumors: Current Progress and Overview","volume":"4","author":"Liu","year":"2014","journal-title":"Theranostics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer\u2019s disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nature Nanotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1158\/0008-5472.CAN-10-1022","article-title":"EGFRvIII Antibody\u2013Conjugated Iron Oxide Nanoparticles for Magnetic Resonance Imaging\u2013Guided Convection-Enhanced Delivery and Targeted Therapy of GlioblastomaEGFRvIII-Targeted Therapy of GBM by IONPs after CED","volume":"70","author":"Hadjipanayis","year":"2010","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/brain\/awr075","article-title":"The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson\u2019s disease: Support from functional MRI","volume":"134","author":"MacDonald","year":"2011","journal-title":"Brain"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","article-title":"Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: A mini review","volume":"23","author":"Kulkarni","year":"2015","journal-title":"J. Drug Target."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijpharm.2011.10.039","article-title":"Oil based nanocarrier system for transdermal delivery of ropinirole: A mechanistic, pharmacokinetic and biochemical investigation","volume":"422","author":"Azeem","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","article-title":"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model","volume":"48","author":"Md","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.nano.2014.12.014","article-title":"Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases","volume":"11","author":"Gendelman","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2009.09.032","article-title":"Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model","volume":"290","author":"Huang","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/jgm.1189","article-title":"Gene transfer into guinea pig cochlea using adeno-associated virus vectors","volume":"10","author":"Konishi","year":"2008","journal-title":"J. Gene Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0167-7799(97)01036-6","article-title":"Biomedical applications of nanotechnology\u2014Implications for drug targeting and gene therapy","volume":"15","author":"Davis","year":"1997","journal-title":"Trends Biotechnol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3727\/096368909X12483162196881","article-title":"Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons","volume":"18","author":"Yurek","year":"2009","journal-title":"Cell Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.addr.2011.10.007","article-title":"Nanotechnological advances for the delivery of CNS therapeutics","volume":"64","author":"Wong","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.wneu.2011.02.016","article-title":"Visualizing the future: Enhancing neuroimaging with nanotechnology","volume":"75","author":"Winer","year":"2011","journal-title":"World Neurosurg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: Combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"15076","DOI":"10.1038\/srep15076","article-title":"Blood-brain barrier opening in behaving non-human primates via focused ultrasound with systemically administered microbubbles","volume":"5","author":"Downs","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.2147\/IJN.S208332","article-title":"Curcumin-loaded nanoparticles: A novel therapeutic strategy in treatment of central nervous system disorders","volume":"14","author":"Pirzadeh","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2015.12.013","article-title":"Targeting specific cells in the brain with nanomedicines for CNS therapies","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/jphp.13132","article-title":"Advancements in nanotherapeutics for Alzheimer\u2019s disease: Current perspectives","volume":"71","author":"Harilal","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40580-018-0168-8","article-title":"Therapeutic nanoplatforms and delivery strategies for neurological disorders","volume":"5","author":"Kang","year":"2018","journal-title":"Nano Converg."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-019-0068-3","article-title":"Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles","volume":"4","author":"Singh","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"119491","DOI":"10.1016\/j.biomaterials.2019.119491","article-title":"Nanomaterial-based blood-brain-barrier (BBB) crossing strategies","volume":"224","author":"Xie","year":"2019","journal-title":"Biomaterials"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.08.008","article-title":"Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?","volume":"71","author":"Kreuter","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.addr.2012.08.012","article-title":"Polymer therapeutics-prospects for 21st century: The end of the beginning","volume":"65","author":"Duncan","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kolb-M\u00e4urer, A., Sunderk\u00f6tter, C., Kukowski, B., and Meuth, S.G. (2019). An update on Peginterferon beta-1a Management in Multiple Sclerosis: Results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1354-y"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-58709-w","article-title":"Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis","volume":"10","author":"Robinson","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer\u2019s disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.pharep.2018.05.008","article-title":"Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators","volume":"70","author":"Dolati","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s13311-018-0606-7","article-title":"Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A pilot randomized clinical trial","volume":"15","author":"Ahmadi","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/10717544.2017.1344334","article-title":"Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma","volume":"24","author":"Zhang","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1158\/1535-7163.MCT-06-0480","article-title":"Interleukin-13 receptor\u2013targeted nanovesicles are a potential therapy for glioblastoma multiforme","volume":"5","author":"Madhankumar","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Mahmud, H., Kasai, T., Khayrani, A.C., Asakura, M., Oo, A.K.K., Du, J., Vaidyanath, A., El-Ghlban, S., Mizutani, A., and Seno, A. (2018). Targeting glioblastoma cells expressing CD44 with liposomes encapsulating doxorubicin and displaying chlorotoxin-IgG Fc fusion protein. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030659"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3109\/03639049809082370","article-title":"Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism","volume":"24","author":"Jain","year":"1998","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/1061186X.2011.595490","article-title":"Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson\u2019s disease in the MPTP-induced mice model","volume":"20","author":"Xiang","year":"2012","journal-title":"J. Drug Target."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.addr.2012.07.002","article-title":"Exosomes are endogenous nanoparticles that can deliver biological information between cells","volume":"65","author":"Sun","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1039\/C4NR04853A","article-title":"Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors","volume":"7","author":"Dixit","year":"2015","journal-title":"Nanoscale"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1605563","DOI":"10.1002\/adma.201605563","article-title":"Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors","volume":"29","author":"Lee","year":"2017","journal-title":"Adv. Mater."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11481-016-9690-9","article-title":"Cell mediated photothermal therapy of brain tumors","volume":"12","author":"Hirschberg","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","article-title":"Neuroprotective effect of gold nanoparticles composites in Parkinson\u2019s disease model","volume":"14","author":"Hu","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/chem.201404562","article-title":"Gold-Nanoparticle-Based Multifunctional Amyloid-\u03b2 Inhibitor against Alzheimer\u2019s Disease","volume":"21","author":"Gao","year":"2015","journal-title":"Chem.\u2013A Eur. J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1016\/j.biomaterials.2012.03.058","article-title":"Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles","volume":"33","author":"Gao","year":"2012","journal-title":"Biomaterials"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG\u2013PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10611860903046628","article-title":"Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic\u00ae P85, an in vitro cell line and in vivo biodistribution studies on rat model","volume":"17","author":"Shah","year":"2009","journal-title":"J. Drug Target."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1038\/srep16589","article-title":"Improved anti-glioblastoma efficacy by IL-13R\u03b12 mediated copolymer nanoparticles loaded with paclitaxel","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.biomaterials.2011.02.044","article-title":"Angiopep-conjugated poly (ethylene glycol)-co-poly (\u03b5-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma","volume":"32","author":"Xin","year":"2011","journal-title":"Biomaterials"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3109\/03639045.2014.991400","article-title":"Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting","volume":"41","author":"Jafarieh","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"246148","DOI":"10.5607\/en.2014.23.3.246","article-title":"Increasing the Efficiency of Parkinson\u2019s Disease Treatment Using a poly (lactic-co-glycolic acid)(PLGA) Based L-DOPA Delivery System","volume":"23","author":"Gambaryan","year":"2014","journal-title":"Exp. Neurobiol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.freeradbiomed.2013.07.042","article-title":"Nicotine-encapsulated poly (lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism","volume":"65","author":"Tiwari","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1074\/jbc.M805956200","article-title":"Functional protein delivery into neurons using polymeric nanoparticles","volume":"284","author":"Hasadsri","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/mp900306x","article-title":"ApoE3 mediated poly (butyl) cyanoacrylate nanoparticles containing curcumin: Study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model","volume":"7","author":"Mulik","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/wnan.59","article-title":"Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer\u2019s disease","volume":"2","author":"Kulkarni","year":"2010","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":": 1710","DOI":"10.1158\/1535-7163.MCT-06-0289","article-title":"A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats","volume":"5","author":"Garcion","year":"2006","journal-title":"Mol. Cancer Therap."},{"key":"ref_154","first-page":"337","article-title":"Umbilical cord mesenchymal stem cells labeled with multimodal iron oxide nanoparticles with fluorescent and magnetic properties: Application for in vivo cell tracking","volume":"9","author":"Sibov","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-121171","article-title":"SPION-enhanced magnetic resonance imaging of Alzheimer\u2019s disease plaques in A\u03b2PP\/PS-1 transgenic mouse brain","volume":"34","author":"Sillerud","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: Bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.mp.4001220","article-title":"Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt\u2013Jakob disease from other dementias","volume":"8","author":"Riemenschneider","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: A summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/CON.0000000000000536","article-title":"2016 World Health Organization classification of central nervous system tumors","volume":"23","author":"Wen","year":"2017","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"9516","DOI":"10.1021\/acsami.7b01171","article-title":"Small-sized mPEG\u2013PLGA nanoparticles of Schisantherin A with sustained release for enhanced brain uptake and anti-parkinsonian activity","volume":"9","author":"Chen","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2005.11.040","article-title":"Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles","volume":"310","author":"Gao","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2006.02.014","article-title":"Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition","volume":"112","author":"Lamprecht","year":"2006","journal-title":"J. Control. Release"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.msec.2017.02.008","article-title":"TPGS-chitosan cross-linked targeted nanoparticles for effective brain cancer therapy","volume":"74","author":"Agrawal","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.colsurfb.2017.01.021","article-title":"Bioadhesive micelles of d-\u03b1-tocopherol polyethylene glycol succinate 1000: Synergism of chitosan and transferrin in targeted drug delivery","volume":"152","author":"Agrawal","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/mp700086j","article-title":"Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: Enhanced efficacy and intratumoral transport capability","volume":"5","author":"Dhanikula","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.biomaterials.2010.09.002","article-title":"PEGylated Poly (amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors","volume":"32","author":"He","year":"2011","journal-title":"Biomaterials"},{"key":"ref_169","first-page":"351031","article-title":"Application of nanoparticles on diagnosis and therapy in gliomas","volume":"2013","author":"Pineda","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1124\/jpet.102.039669","article-title":"Poly (ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting","volume":"303","author":"Brigger","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: Review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-013-1302-4","article-title":"Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma","volume":"116","author":"Spratt","year":"2014","journal-title":"J. Neuro-Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3174\/ajnr.A4374","article-title":"Repeatability of standardized and normalized relative CBV in patients with newly diagnosed glioblastoma","volume":"36","author":"Prah","year":"2015","journal-title":"Am. J. Neuroradiol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneurol.2009.159","article-title":"Antiangiogenic therapies for high-grade glioma","volume":"5","author":"Norden","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1012245115209","article-title":"Extraneural metastases of primary brain tumors","volume":"53","author":"Schweitzer","year":"2001","journal-title":"J. Neuro-Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Hanssen, A., Riebensahm, C., Mohme, M., Joosse, S., Velthaus, J.-L., Berger, L., Bernreuther, C., Glatzel, M., Loges, S., and Lamszus, K. (2018). Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease. Cancers, 10.","DOI":"10.3390\/cancers10120527"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2159-8290.CD-14-0471","article-title":"Brain tumor cells in circulation are enriched for mesenchymal gene expression","volume":"4","author":"Sullivan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1365-2567.2002.01507.x","article-title":"All in the head: Obstacles for immune rejection of brain tumours","volume":"107","author":"Walker","year":"2002","journal-title":"Immunology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","article-title":"The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms","volume":"26","author":"Engelhardt","year":"2005","journal-title":"Trends Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1469-7580.2002.00065.x","article-title":"Blood\u2013brain barrier breakdown in septic encephalopathy and brain tumours","volume":"200","author":"Davies","year":"2002","journal-title":"J. Anat."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00401-002-0524-x","article-title":"Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: Spatial segregation of tenascin and agrin","volume":"104","author":"Rascher","year":"2002","journal-title":"Acta Neuropathol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.2741\/1465","article-title":"Cellular immunity and immunotherapy of brain tumors","volume":"9","author":"Prins","year":"2004","journal-title":"Front. Biosci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.4049\/jimmunol.172.9.5149","article-title":"Cutting edge: TGF-\u03b2 induces a regulatory phenotype in CD4+ CD25\u2212 T cells through Foxp3 induction and down-regulation of Smad7","volume":"172","author":"Fantini","year":"2004","journal-title":"J. Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-\u03b2 regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma","volume":"66","author":"Fecci","year":"2006","journal-title":"Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-005-9103-z","article-title":"Inhibition of hypoxia inducible factor-1\u03b1 (HIF-1\u03b1) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas","volume":"78","author":"Jensen","year":"2006","journal-title":"J. Neuro-Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1158\/1078-0432.CCR-10-2557","article-title":"Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-\u03b2","volume":"17","author":"Lohr","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_188","first-page":"959","article-title":"Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3","volume":"21","author":"Lang","year":"2017","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_189","unstructured":"Caffo, M., Barresi, V., Caruso, G., La Fata, G., Pino, M.A., Raudino, G., Alafaci, C., and Tomasello, F. (2013). Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications, IntechOpen."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1126\/science.1063916","article-title":"Regulation of cutaneous malignancy by \u03b3\u03b4 T cells","volume":"294","author":"Girardi","year":"2001","journal-title":"Science"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Chokshi, C.R., Brakel, B.A., Tatari, N., Savage, N., Salim, S.K., Venugopal, C., and Singh, S.K. (2021). Advances in immunotherapy for adult glioblastoma. Cancers, 13.","DOI":"10.3390\/cancers13143400"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nrneurol.2017.64","article-title":"Vaccine-based immunotherapeutic approaches to gliomas and beyond","volume":"13","author":"Weller","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2017.05.064","article-title":"The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme","volume":"810","author":"Chistiakov","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Reardon, D.A., Schuster, J., Tran, D.D., Fink, K.L., Nabors, L.B., Li, G., Bota, D.A., Lukas, R.V., Desjardins, A., and Ashby, L.S. (2015). ReACT: Overall Survival from a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma, American Society of Clinical Oncology.","DOI":"10.1200\/jco.2015.33.15_suppl.2009"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41568-019-0118-8","article-title":"Glioblastoma is \u2018hot\u2019for personalized vaccines","volume":"19","author":"Baratta","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2017.06.006","article-title":"Engineering challenges for brain tumor immunotherapy","volume":"114","author":"Lyon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1800128","DOI":"10.1002\/adtp.201800128","article-title":"Advancing Cancer Immunotherapies with Nanotechnology","volume":"2","author":"Lou","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jconrel.2018.09.010","article-title":"Recent advances in applying nanotechnologies for cancer immunotherapy","volume":"288","author":"Mahjub","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.neuroimage.2007.03.078","article-title":"Internalization of MWCNTs by microglia: Possible application in immunotherapy of brain tumors","volume":"37","author":"Kateb","year":"2007","journal-title":"NeuroImage"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","article-title":"Nanoparticle delivery systems in cancer vaccines","volume":"28","author":"Krishnamachari","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1705054","DOI":"10.1002\/adma.201705054","article-title":"Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi-Based Immunochemotherapy of Intracranial Glioblastoma Treatment","volume":"30","author":"Qiao","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1158\/0008-5472.CAN-18-2725","article-title":"Blockade of a Laminin-411\u2013Notch Axis with CRISPR\/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk","volume":"79","author":"Sun","year":"2019","journal-title":"Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1039\/C8MH01286E","article-title":"Hybrid \u2018clusterbombs\u2019 as multifunctional nanoplatforms potentiate brain tumor immunotherapy","volume":"6","author":"Shen","year":"2019","journal-title":"Mater. Horiz."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2017.09.022","article-title":"Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma","volume":"411","author":"Liu","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","article-title":"Nanoparticles that reshape the tumor milieu create a therapeutic window for effective t-cell therapy in solid malignancies","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2018.10.034","article-title":"Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes","volume":"292","author":"Shi","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.2147\/IJN.S164611","article-title":"Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment","volume":"13","author":"Peng","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","article-title":"Blood\u2013brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy","volume":"10","author":"Galstyan","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ijpharm.2015.09.062","article-title":"Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma","volume":"495","author":"Lollo","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/imt.12.148","article-title":"The future of CpG immunotherapy in cancer","volume":"5","author":"Badie","year":"2013","journal-title":"Immunotherapy"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijpharm.2019.01.042","article-title":"Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment","volume":"559","author":"Bastiancich","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts SurvivalIDO Regulates Treg Infiltration in Brain Tumors","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clinic. Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrc2639","article-title":"Inhibitors of indoleamine-2, 3-dioxygenase for cancer therapy: Can we see the wood for the trees?","volume":"9","author":"Rammensee","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","article-title":"Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses","volume":"67","author":"Hou","year":"2007","journal-title":"Cancer Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1800025","DOI":"10.1002\/adfm.201800025","article-title":"iRGD Modified Chemo-immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma","volume":"28","author":"Kuang","year":"2018","journal-title":"Adv. Funct. Mater."},{"key":"ref_221","first-page":"1365","article-title":"High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme","volume":"13","author":"Kadiyala","year":"2019","journal-title":"ACS Nano"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41598-017-01279-1","article-title":"Sensitization of glioblastoma tumor micro-environment to chemo-and immunotherapy by Galectin-1 intranasal knock-down strategy","volume":"7","author":"Mathivet","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2016.11.001","article-title":"Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme","volume":"244","author":"Chou","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biomaterials.2019.04.020","article-title":"Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo","volume":"209","author":"Kozielski","year":"2019","journal-title":"Biomaterials"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood\u2013brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lfs.2017.08.027","article-title":"RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials","volume":"188","year":"2017","journal-title":"Life Sci."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/156652309789753301","article-title":"Gene therapy for brain cancer: Combination therapies provide enhanced efficacy and safety","volume":"9","author":"Candolfi","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/ijc.32531","article-title":"A tumor-targeting nanomedicine carrying the p53 gene crosses the blood\u2013brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma","volume":"145","author":"Kim","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/neuonc\/nox139","article-title":"Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma","volume":"20","author":"Speranza","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41467-019-08390-z","article-title":"The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma","volume":"10","author":"Bhaskaran","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: Non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Zhao, C.-Y., Cheng, R., Yang, Z., and Tian, Z.-M. (2018). Nanotechnology for cancer therapy based on chemotherapy. Molecules, 23.","DOI":"10.3390\/molecules23040826"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"119283","DOI":"10.1016\/j.ijpharm.2020.119283","article-title":"Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy","volume":"581","author":"Lorenzoni","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.7150\/thno.40298","article-title":"Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.7150\/thno.22736","article-title":"Targeting tumor hypoxia using nanoparticle-engineered CXCR4-overexpressing adipose-derived stem cells","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2018.10.004","article-title":"Recent progress of drug nanoformulations targeting to brain","volume":"291","author":"Khan","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2018.05.008","article-title":"Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment","volume":"281","author":"Ganipineni","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer\u2019s disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/npp.2013.154","article-title":"Biomarkers in amyloid-\u03b2 immunotherapy trials in Alzheimer\u2019s disease","volume":"39","author":"Blennow","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Delacourte","year":"2000","journal-title":"Brain Res. Rev."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4103\/1673-5374.266046","article-title":"Can mouse models mimic sporadic Alzheimer\u2019s disease?","volume":"15","author":"Foidl","year":"2020","journal-title":"Neural Reg. Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.peptides.2006.04.022","article-title":"PEGylated phospholipid nanomicelles interact with \u03b2-amyloid (1\u201342) and mitigate its \u03b2-sheet formation, aggregation and neurotoxicity in vitro","volume":"27","author":"Pai","year":"2006","journal-title":"Peptides"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nano.2011.06.015","article-title":"Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer\u2019s A\u03b2 peptide","volume":"7","author":"Taylor","year":"2011","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-510X(98)00092-6","article-title":"Copper, iron and zinc in Alzheimer\u2019s disease senile plaques","volume":"158","author":"Lovell","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpb.2004.07.009","article-title":"Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer\u2019s and other CNS diseases","volume":"59","author":"Cui","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1166\/jnn.2007.330","article-title":"Effects of hydrated forms of C60 fullerene on amyloid \u03b2-peptide fibrillization in vitro and performance of the cognitive task","volume":"7","author":"Podolski","year":"2007","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.nano.2009.11.007","article-title":"Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease","volume":"6","author":"Yang","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1242\/jcs.113.11.1857","article-title":"Proteolytic processing and cell biological functions of the amyloid precursor protein","volume":"113","author":"Annaert","year":"2000","journal-title":"J Cell Sci"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0962-8924(98)01363-4","article-title":"The cell biology of \u03b2-amyloid precursor protein and presenilin in Alzheimer\u2019s disease","volume":"8","author":"Selkoe","year":"1998","journal-title":"Trends Cell Bio."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.phrs.2003.12.028","article-title":"The role of beta amyloid in Alzheimer\u2019s disease: Still a cause of everything or the only one who got caught?","volume":"50","author":"Verdile","year":"2004","journal-title":"Pharmacol. Res."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12017-014-8318-6","article-title":"Apolipoprotein E isoform-specific effects on lipoprotein receptor processing","volume":"16","author":"Bachmeier","year":"2014","journal-title":"NeuroMol. Med."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","article-title":"Apolipoprotein E, Receptors, and Modulation of Alzheimer\u2019s Disease","volume":"83","author":"Zhao","year":"2018","journal-title":"Biol Psychiatry"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.07.008","article-title":"Low-density lipoprotein receptor-related protein 1: A physiological A\u03b2 homeostatic mechanism with multiple therapeutic opportunities","volume":"136","author":"Sagare","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ddr.10081","article-title":"Current drug targets for Alzheimer\u2019s disease treatment","volume":"56","author":"Lahiri","year":"2002","journal-title":"Drug Dev. Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharma.2013.04.001","article-title":"Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: The example of Alzheimer\u2019s disease","volume":"71","author":"Andrieux","year":"2013","journal-title":"Ann. Pharm. Fr."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0197-4580(01)00289-5","article-title":"Inflammation, autotoxicity and Alzheimer disease","volume":"22","author":"McGeer","year":"2001","journal-title":"Neurobio. Aging"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: A case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nm0204-117","article-title":"Specificity of mechanisms for plaque removal after A\u03b2 immunotherapy for Alzheimer disease","volume":"10","author":"Akiyama","year":"2004","journal-title":"Nat. Med."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/87945","article-title":"TGF-\u03b21 promotes microglial amyloid-\u03b2 clearance and reduces plaque burden in transgenic mice","volume":"7","author":"Lin","year":"2001","journal-title":"Nat. Med."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1073\/pnas.162350199","article-title":"Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer\u2019s mice","volume":"99","author":"Yan","year":"2002","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nri1843","article-title":"Immunology and immunotherapy of Alzheimer\u2019s disease","volume":"6","author":"Weiner","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1901555","DOI":"10.1002\/advs.201901555","article-title":"An \u201cAmyloid-\u03b2 Cleaner\u201d for the Treatment of Alzheimer\u2019s Disease by Normalizing Microglial Dysfunction","volume":"7","author":"Liu","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_267","first-page":"45","article-title":"Advances in the development of antibody-based immunotherapy against prion disease","volume":"4","author":"Gu","year":"2014","journal-title":"Antib. Technol. J."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt237","article-title":"Active immunotherapy options for Alzheimer\u2019s disease","volume":"6","author":"Winblad","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awz100","article-title":"Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody","volume":"142","author":"Albert","year":"2019","journal-title":"Brain"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbapap.2014.08.016","article-title":"Antibodies and protein misfolding: From structural research tools to therapeutic strategies","volume":"1844","author":"Messer","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., and Karaman, R. (2020). Comprehensive review on Alzheimer\u2019s disease: Causes and treatment. Molecules, 25.","DOI":"10.3390\/molecules25245789"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nan.12297","article-title":"Parkinson\u2019s disease: From synaptic loss to connectome dysfunction","volume":"42","author":"Bellucci","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: Mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","article-title":"Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in \u03b1-synuclein models of Parkinson\u2019s and Lewy body diseases","volume":"29","author":"Spencer","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrneurol.2013.275","article-title":"Extracellular \u03b1-synuclein\u2014A novel and crucial factor in Lewy body diseases","volume":"10","author":"Lee","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Stoddard-Bennett, T., and Reijo Pera, R. (2019). Treatment of Parkinson\u2019s Disease through Personalized Medicine and Induced Pluripotent Stem Cells. Cells, 8.","DOI":"10.3390\/cells8010026"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jnnp-2015-312036","article-title":"Induced pluripotent stem cells in Parkinson\u2019s disease: Scientific and clinical challenges","volume":"87","author":"Xiao","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11910-011-0197-8","article-title":"An update on gene therapy in Parkinson\u2019s disease","volume":"11","author":"Witt","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/bc034164r","article-title":"Nanogels for oligonucleotide delivery to the brain","volume":"15","author":"Vinogradov","year":"2004","journal-title":"Bioconjugate Chem."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10611860903112842","article-title":"Brain targeting of nerve growth factor using poly (butyl cyanoacrylate) nanoparticles","volume":"17","author":"Kurakhmaeva","year":"2009","journal-title":"J. Drug Target."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/jbm.b.32888","article-title":"Development of poly (butylene succinate) microspheres for delivery of levodopa in the treatment of parkinson\u2019s disease","volume":"101","author":"Mohanraj","year":"2013","journal-title":"J. Biomed. Mater. Res. Part B: Appl. Biomater."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fnagi.2018.00370","article-title":"New perspectives on roles of alpha-synuclein in Parkinson\u2019s disease","volume":"10","author":"Zhang","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ncpneuro0222","article-title":"Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease","volume":"2","author":"Olanow","year":"2006","journal-title":"Nat. Rev. Neurol."},{"key":"ref_285","unstructured":"Moloney, K.K. (2011). Age and IFN-Gamma Deficiency Modulate the Impact of Repeated Paraquat Exposure in a Mouse Model of Parkinson\u2019s Disease, Carleton University."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/glia.22311","article-title":"Blood-brain barrier dysfunction, TGF\u03b2 signaling, and astrocyte dysfunction in epilepsy","volume":"60","author":"Heinemann","year":"2012","journal-title":"Glia"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: From structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jnc.13529","article-title":"Therapeutic approaches in Parkinson\u2019s disease and related disorders","volume":"139","author":"Valera","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: Implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., and Rohn, T.T. (2011). Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019338"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Roodveldt, C., Labrador-Garrido, A., Gonzalez-Rey, E., Lachaud, C.C., Guilliams, T., Fernandez-Montesinos, R., Benitez-Rondan, A., Robledo, G., Hmadcha, A., and Delgado, M. (2013). Preconditioning of microglia by \u03b1-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079160"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41565-018-0179-y","article-title":"Graphene quantum dots prevent \u03b1-synucleinopathy in Parkinson\u2019s disease","volume":"13","author":"Kim","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"ref_295","unstructured":"Bates, G., Dorsey, R., and Gusella, J. Nat Rev Dis Primers. 2015."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"22480","DOI":"10.1073\/pnas.0911503106","article-title":"Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms","volume":"106","author":"Bradford","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"2525967","DOI":"10.1155\/2017\/2525967","article-title":"Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications","volume":"2017","author":"Liu","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/1097-4547(20001115)62:4<600::AID-JNR15>3.0.CO;2-F","article-title":"Polyhydroxylated C60, fullerenols, as glutamate receptor antagonists and neuroprotective agents","volume":"62","author":"Jin","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/mp3003946","article-title":"Self-assembling modified \u03b2-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: Focus on Huntington\u2019s disease","volume":"10","author":"Godinho","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12017-013-8261-y","article-title":"Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington\u2019s disease","volume":"16","author":"Sandhir","year":"2014","journal-title":"Neuromolecular Med."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"34725","DOI":"10.1021\/acsami.9b12319","article-title":"Selenium nanoparticles as an efficient nanomedicine for the therapy of Huntington\u2019s disease","volume":"11","author":"Cong","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_303","first-page":"742","article-title":"Progress in nanomedicine: Approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nnano.2017.67","article-title":"The evolving landscape of drug products containing nanomaterials in the United States","volume":"12","author":"Cruz","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","article-title":"Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme","volume":"103","author":"Ulrich","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1016\/j.wneu.2018.06.114","article-title":"Convection-enhanced delivery of polymeric nanoparticles encapsulating chemotherapy in canines with spontaneous supratentorial tumors","volume":"117","author":"Young","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_307","first-page":"874","article-title":"The neuromodulatory effects of \u03c9-3 fatty acids and nano-curcumin on the COX-2\/iNOS network in migraines: A clinical trial study from gene expression to clinical symptoms","volume":"19","author":"Abdolahi","year":"2019","journal-title":"Endocr. Metab. Immune Disord. -Drug Targets (Former. Curr. Drug Targets-Immune Endocr. Metab. Disord.)"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00251-017-0992-8","article-title":"The synergistic effects of \u03c9-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-\u03b1 gene expression and serum level in migraine patients","volume":"69","author":"Abdolahi","year":"2017","journal-title":"Immunogenetics"},{"key":"ref_309","first-page":"1120","article-title":"The combined effects of \u03c9-3 fatty acids and nano-curcumin supplementation on intercellular adhesion molecule-1 (ICAM-1) gene expression and serum levels in migraine patients","volume":"16","author":"Soveyd","year":"2017","journal-title":"CNS Neurol. Disord. -Drug Targets (Former. Curr. Drug Targets-CNS Neurol. Disord.)"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12028-008-9071-1","article-title":"Efficacy of silver nanoparticles-impregnated external ventricular drain catheters in patients with acute occlusive hydrocephalus","volume":"8","author":"Lackner","year":"2008","journal-title":"Neurocritical Care"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-018-03005-x","article-title":"Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients","volume":"141","author":"Grauer","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1161\/STROKEAHA.107.481788","article-title":"Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke","volume":"38","author":"Saleh","year":"2007","journal-title":"Stroke"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/3\/1283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:18:30Z","timestamp":1760120310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/3\/1283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":312,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["molecules28031283"],"URL":"https:\/\/doi.org\/10.3390\/molecules28031283","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]}}}